In a recent study published in Life Metabolism, researchers at Fudan University report that even after stopping the anti-obesity drug tirzepatide, ...

Eli Lilly says GIP/GLP-1 agonist tirzepatide can reduce the risk of diabetes in overweight, obese people with prediabetes.

Eli Lilly's dual GLP-1/GIP agonist tirzepatide has been shown to reduce the risk of worsening disease in people with heart failure and obesity in a phase 3 trial, the first to show a benefit on ...

Weight loss results on Zepbound vary between people, but clinical trials have reported weight loss of more than 10% of body weight in people taking tirzepatide for 72 weeks.